Crown Bioscience Launches '3D Ex Vivo Patient Tissue Platform' to Improve Response Predictability to Immuno-Oncology Drug Candidates
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
SUNNYVALE, California -- Businesswire -- Crown Bioscience, a JSR Life Sciences company and leader in translational services that help biopharmaceutical companies accelerate new drug development programs, today announced the launch of its '3D Ex Vivo Patient Tissue Platform'.
"Our goal is to leverage our core technologies to build a translational model system that adequately captures the tumor architecture and microenvironment, and improves the predictability of patient responses to treatment protocols for existing and potential therapeutic candidates," said Leo Price, PhD, Senior Vice President, In Vitro. "We believe this approach provides greater translational relevance in drug development by using immuno-competent primary human tumor tissue to help analyze drug candidate responses before the program enters clinical trial. This approach is an optimal fit with our mission to help deliver the right drug to the right patient at the right time."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SUNNYVALE, California -- Businesswire -- Crown Bioscience, a JSR Life Sciences company and leader in translational services that help biopharmaceutical companies accelerate new drug development programs, today announced the launch of its ‘3D Ex Vivo Patient Tissue Platform’. Using freshly collected patient tumor material, this new service can accurately measure oncology and immuno-oncology drug-induced tumor killing and endogenous immune cell proliferation in a high throughput format. Researchers are presenting data on the new platform at this year’s AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is happening virtually on October 7-10, 2021.
The proprietary technology, developed at Crown Bioscience’s recently acquired site in Leiden, The Netherlands (formerly known as OcellO B.V.), aims to improve clinical success rates by using the most patient-relevant tumor samples to better predict tumor response to potential drug candidates.
“Our goal is to leverage our core technologies to build a translational model system that adequately captures the tumor architecture and microenvironment, and improves the predictability of patient responses to treatment protocols for existing and potential therapeutic candidates,” said Leo Price, PhD, Senior Vice President, In Vitro. “We believe this approach provides greater translational relevance in drug development by using immuno-competent primary human tumor tissue to help analyze drug candidate responses before the program enters clinical trial. This approach is an optimal fit with our mission to help deliver the right drug to the right patient at the right time.”
The ‘3D Ex Vivo Patient Tissue Platform’ utilizes patient tumor tissue isolated from biopsies, surgical resections, ascites, or pleural effusion samples that are processed within 24 hours to preserve the tumor microenvironment. The automated high throughput platform uses high content 3D imaging and image analysis to quantify distinct responses of individual cell populations in fresh patient tissues. These analyses can assess responses to different doses of therapeutic candidates at various timepoints and can determine the effects of the drug or combination of drugs on tumor killing and immune cell proliferation.
“We believe this new service can help fill a critical gap in today’s research landscape with early translational patient-relevant ex vivo models that can assess efficacy and determine mechanisms of action,” commented Armin Spura, PhD, Chief Executive Officer of Crown Bioscience. “This new service offering is designed to help mitigate the high failure rates of clinical programs in oncology, and was one of the objectives coming out of our recent OcellO acquisition. We are delighted to provide immediate value to our customers from this investment and look forward to the future value that this acquisition will bring.”
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Researchers from CrownBio are conducting a poster presentation titled, “Novel Near Vivo Drug Response Platform for Oncology using 3D Ex Vivo Patient-Derived Microtumors” at the annual conference. The poster summarizes:
· This 3D high content assay on ex vivo patient tumor material preserves native tumor microenvironement and architecture · Ex vivo testing using ultra fresh patient tumor samples maintains intact endogenous immune cell populations · Ongoing clinical trial collaborations with tissue providers for ovarian cancer, bladder cancer, NSCLC, and other tumor samples
For more information on Crown Bioscience’s 3D Ex Vivo Patient Tissue Platform, visit Crown Bioscienes's webpage on the new service. https://bit.ly/3lmLyDl
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development services company providing translational platforms to advance oncology, immuno-oncology, and immune mediated inflammatory disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005565/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Crown Bioscience Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자 ‘삼성 개발자 콘퍼런스 2024’ 개최 - 뉴스와이어
- 국내 최대 시상금 규모… 제1회 삼익 아마추어 콩쿠르 11월 개최 - 뉴스와이어
- 아모레퍼시픽, 프랑스 칸 ‘2024 TFWA 세계면세박람회’ 참가 - 뉴스와이어
- ‘진짜 두바이 초콜릿’이 왔다… 오리지널 중동의 맛 블린더 초콜릿, 한국 정식 출시 - 뉴스와
- GS샵 ‘궁키친 이상민’ 간편식 6개월 만에 누적 판매 60억원 돌파 - 뉴스와이어
- 대한전선, 싱가포르서 8400억 수주 - 뉴스와이어
- 삼성전자, 업계 최고 성능·최대 용량 PC용 SSD PM9E1 양산 - 뉴스와이어
- 좋은땅출판사 ‘주식으로 떠나는 은퇴 여행’ 출간 - 뉴스와이어
- ‘오대꽃밥’ 귀한 꽃으로 피어나는 철원 오대쌀 축제 - 뉴스와이어
- 템퍼, 미국우주재단 인증 26주년 기념 ‘템퍼 유니버스’ 프로모션 진행 - 뉴스와이어